Mektovi (binimetinib tablets – Array BioPharma) — Cigna
Non-Small Cell Lung Cancer
Initial criteria
- Patient is age ≥ 18 years
- Patient has recurrent, advanced, or metastatic disease
- Patient has BRAF V600E mutation-positive disease
- The medication will be used in combination with Braftovi (encorafenib capsules)
Approval duration
1 year